Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Change in Receivables (2022 - 2025)

Historic Change in Receivables for Addex Therapeutics (ADXN) over the last 4 years, with Q2 2025 value amounting to $24.0 billion.

  • Addex Therapeutics' Change in Receivables rose 26843.29% to $24.0 billion in Q2 2025 from the same period last year, while for Jun 2025 it was -$2.8 billion, marking a year-over-year increase of 9845.17%. This contributed to the annual value of $105834.9 for FY2024, which is 6898.94% down from last year.
  • Per Addex Therapeutics' latest filing, its Change in Receivables stood at $24.0 billion for Q2 2025, which was up 26843.29% from -$22.1 billion recorded in Q1 2025.
  • In the past 5 years, Addex Therapeutics' Change in Receivables ranged from a high of $423.9 billion in Q4 2024 and a low of -$428.7 billion during Q3 2024
  • For the 4-year period, Addex Therapeutics' Change in Receivables averaged around -$368.0 million, with its median value being $35852.7 (2022).
  • Examining YoY changes over the last 5 years, Addex Therapeutics' Change in Receivables showed a top increase of 49263110067.45% in 2023 and a maximum decrease of 21192830407.82% in 2023.
  • Addex Therapeutics' Change in Receivables (Quarter) stood at -$123736.3 in 2022, then tumbled by 211928304.08% to -$262.2 billion in 2023, then skyrocketed by 261.67% to $423.9 billion in 2024, then crashed by 94.34% to $24.0 billion in 2025.
  • Its Change in Receivables stands at $24.0 billion for Q2 2025, versus -$22.1 billion for Q1 2025 and $423.9 billion for Q4 2024.